ACRV

Rating neutralAI Memo

Acrivon Therapeutics

As of 2026-05-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Second-half 2026 simultaneous interim update from the serous endometrial cancer arms • 2026-09-15

Expected move: -8%

Biggest risk

Any slip in Phase 3 readiness, weaker interim data, or renewed financing/dilution pressure could keep the stock stuck in event-risk mode.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Acrivon can re-rate if ACR-368 stays on the stated Phase 3 path and the second-half 2026 interim update supports the signal, while runway into Q3 2027 keeps financing pressure manageable.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-29

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Phase 3 readiness remains the next execution checkpoint for ACR-368
Runway into the third quarter of 2027 lowers immediate financing stress but not dilution risk
Acrivon can re-rate if ACR-368 stays on the stated Phase 3 path and the second-half 2026 interim update supports the signal, while runway into Q3 2027 keeps financing pressure manageable.

BearKey bullets

Dilution or financing overhang persists despite runway into Q3 2027, especially given the company's small market cap and development-stage profile.
Low coverage means there is limited analyst corroboration if the story changes quickly.
Timing or regulatory slippage on Phase 3 readiness or the second-half 2026 interim update.

WatchKey bullets

Second-half 2026 simultaneous interim update from the serous endometrial cancer arms

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=50%)

Bull/Bear spread: +104% / -52%

Vs latest close: Bull +104% · Base -8% · Bear -52%

Scenario probabilities

Bull Target: $3 (p=25%)Base Target: $1 (p=50%)Bear Target: $1 (p=25%)

Commentary

Primary-source support is adequate but narrow: the May 13, 2026 SEC filings anchor the thesis to trial timing and runway, but coverage remains limited, no recent trusted-news items were provided, and no usable social context was available. The stock closed at $1.63 on 2026-05-28, and with the deterministic prior still negative across 5d to 120d, this remains a cautious monitoring setup rather than a high-conviction bullish call.

As of 2026-05-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Acrivon can re-rate if ACR-368 stays on the stated Phase 3 path and the second-half 2026 interim update supports the signal, while runway into Q3 2027 keeps financing pressure manageable.

Bear Case

Any slip in Phase 3 readiness, weaker interim data, or renewed financing/dilution pressure could keep the stock stuck in event-risk mode.

Drivers

Scannable catalysts and supporting factors

Phase 3 readiness remains the next execution checkpoint for ACR-368
Runway into the third quarter of 2027 lowers immediate financing stress but not dilution risk

Scenarios

Bull Target (Scenario probability)

$3 / p=25% prob

Base Target (Scenario probability)

$1 / p=50% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Price $2 as of 2026-06-02

Nearest Scenario: Base (∆ 8%)

Targets vs latest close: Bull +104% · Base -8% · Bear -52%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-15
Second-half 2026 simultaneous interim update from the serous endometrial cancer arms
The May 13 company update shifted the clearest rerating event to a prespecified simultaneous interim analysis and data update from both biopsy-independent serous endometrial cancer arms of the ACR-368 Phase 2b study in the second half of 2026 [#8-K-2026-05-13].
Prob 55.00% • Move 60.00% • Priced-in 28.00%

Short-term Catalysts

Next few weeks

Phase 3 readiness remains the next execution checkpoint for ACR-368
2026-06-30
Management said ACR-368 is expected to be ready for a Phase 3 confirmatory trial in combination with PD-1 therapy by mid-2026, so the near-term question is execution on timing and regulatory alignment rather than commercialization [#8-K-2026-05-13].
Prob 50% • Move 20% • Priced-in 40%

Long-term Catalysts

Months to a year

Runway into the third quarter of 2027 lowers immediate financing stress but not dilution risk
2027-09-30
Acrivon reported $97.7 million of cash, cash equivalents and investments at March 31, 2026 and said that, together with $7.3 million of subsequent equity-financing proceeds, it expects to fund operations into the third quarter of 2027 [#10-Q-2026-05-13][#8-K-2026-05-13].
Prob 72% • Move 16% • Priced-in 70%

Risks

Dilution or financing overhang persists despite runway into Q3 2027, especially given the company's small market cap and development-stage profile.
Low coverage means there is limited analyst corroboration if the story changes quickly.
Timing or regulatory slippage on Phase 3 readiness or the second-half 2026 interim update.
Trial readout disappointment or a weaker-than-expected signal in the serous endometrial cancer arms.

Peers

Symbol	Summary
BYSI	Same-sector small-cap biotech comparator; mainly useful for event-driven volatility and financing sensitivity rather than direct pipeline overlap.
EDSA	Another similarly sized biotech peer; helpful for framing binary catalyst risk, rerating potential, and dilution sensitivity.
OTLK	Low-cap biotech comparator that can help benchmark capital-markets sensitivity around clinical or regulatory milestones.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-29

AI Stock Memo: ACRV - Acrivon Therapeutics - RankAlpha